Mitral stenosis pathophysiology
Mitral stenosis microchapters
Mitral stenosis pathophysiology On the Web
American Roentgen Ray Society Images of Mitral stenosis pathophysiology
Mitral stenosis (MS) is most commonly secondary to acute rheumatic fever. Generally, the initial valvulitis is associated with valvular regurgitation but over a period of 2 or more years, the commissures fuse and the valves thicken and calcify. The chordal supporting structure also calcifies and retracts. The result is the typical “fish mouth deformity”. 70% of the time; the mitral valve is involved in isolation, and 25% of the time; the aortic valve is involved as well. The tricuspid and pulmonic valves are involved less commonly. Patients develop symptoms when the mitral vavle area is 2 to 2.5 cm2.
Almost all cases of mitral stenosis are due to disease in the heart secondary to rheumatic fever and the consequent rheumatic heart disease (a condition that may develop after strep throat or scarlet fever). Around 90% of cases of rheumatic heart disease are associated with mitral stenosis. The valve problems develop 5 - 10 years after the rheumatic fever, a tiny nodule forms along the valve leaflets , the leaflets eventually thicken with deposition of fibrin. The cusps may become fibrosed, calcified and thickened over a span of a decade. Chronic turbulent flow through a deformed valve appears to cause these changes and as a result the valve looses it's normal morphology. The degree of leaflet thickening and calcification and the severity of chordal involvement are variable. Rheumatic fever is becoming rare in the United States, so mitral stenosis is also less common.
Hemodynamic Perturbations in Mitral Stenosis
The severity of mitral stenosis depends on the pressure gradient between the left atrium and ventricle which depends on the cross sectional area of the mitral valve. The normal mitral valve orifice has a cross sectional area of about 4.0 cm2.
- Mitral stenosis is mild if the cross sectional area is about 2 cm2 and the pressure gradient is small.
- Mitral stenosis is moderate if the cross sectional area is about 1.0 to 1.5 cm2.
- Mitral stenosis is severe if the cross sectional area is ≤1.0 cm2 and the pressure gradient between the left atrium and left ventricle is significant.
Normal Mitral Valve Anatomy
The normal mitral valve orifice area is 4-6 cm2. Mitral stenosis occurs when the orifice area is reduced to at least 2.2 cm2. This degree of narrowing results in a gradient across the mitral valve. The opening is surrounded by a fibrous ring known as the mitral valve annulus. The anterior cusp covers approximately two-thirds of the valve area (imagine a crescent moon within the circle, where the crescent represents the posterior cusp). These valve leaflets are prevented from prolapsing into the left atrium by the action of tendons attached to the posterior surface of the valve, the chordae tendineae.
The inelastic chordae tendineae are attached at one end to the papillary muscles and at the other end to the valve cusps. Papillary muscles are fingerlike projections that extend from the wall of the left ventricle. Chordae tendineae from each muscle are attached to both leaflets of the mitral valve. Thus, when the left ventricle contracts, the intraventricular pressure forces the valve to close, while the tendons keep the leaflets coapting together and prevent the valve from opening in the wrong direction; thus preventing blood to flow back to the left atrium. Each chord has a different thickness. The thinnest ones are attached to the free leaflet margin, whereas thickest ones are attached quite away from the free margin. This disposition has important effects on systolic stress distribution physiology.
Mild Mitral Stenosis
When the mitral valve cross sectional area is about 2 cm2 and the pressure gradient is small.
Moderate Mitral Stenosis
When the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient across the mitral valve. This gradient may be increased by increases in the heart rate or cardiac output. As the gradient across the mitral valve increases, the amount of time necessary to fill the left ventricle with blood increases. Eventually, the valve is so tight and the gradient is so high that the atrial kick is required to fill the left ventricle with blood. As the heart rate increases, the amount of time that the ventricle is in diastole and can fill up with blood (called the diastolic filling period) decreases. When the heart rate goes above a certain point, the diastolic filling period is insufficient to fill the ventricle with blood and pressure builds up in the left atrium, leading to pulmonary congestion. The patient may experience dyspnea on exertion at this point.
Severe Mitral Stenosis
When the mitral valve area goes less than 1 cm2, there will be a further increase in the left atrial pressures. Since the normal left ventricular diastolic pressures is about 5 mm Hg, a pressure gradient across the mitral valve of 20 mm Hg due to severe mitral stenosis will cause a left atrial pressure of about 25 mm Hg. This left atrial pressure is transmitted to the pulmonary vasculature and causes an elevated pulmonary capillary wedge pressure. Pulmonary capillary pressures in this level cause an imbalance between the hydrostatic pressure and the oncotic pressure, leading to extravasation of fluid from the vascular tree and pooling of fluid in the lungs (congestive heart failure causing pulmonary edema). Increases in the heart rate will allow less time for the left ventricle to fill, also causing an increase in left atrial pressure and further pulmonary congestion causing Hemoptysis may develop. The constant pressure overload of the left atrium will cause the left atrium to increase in size. As the left atrium increases in size, it becomes more prone to develop atrial fibrillation. When atrial fibrillation develops, the atrial kick is lost.
In individuals with severe mitral stenosis, the left ventricular filling is dependent on the atrial kick. The loss of the atrial kick due to atrial fibrillation can cause a precipitous decrease in cardiac output and sudden congestive heart failure. Mitral stenosis may cause left ventricular dysfunction if it is associated with mitral regurgitation.
Right Heart Failure
The elevated pressures in the left atrium are transmitted into the pulmonary circuit, and pulmonary hypertension may develop. Due to hypoxemia, there may be pulmonary vasoconstriction as well that further elevates right heart pressures. The elevated pulmonary capillary wedge pressure leads to a rise in interstitial edema which also increases the load on the right ventricle. Finally, intimal hyperplasia and medial hypertrophy develop in the pulmonary vascular bed.
All the aforementioned changes lead to a rise in the pulmonary arterial pressure and the right ventricle begins to dilate and fail. As a result of the dilation of the right ventricle, tricuspid regurgitation develops. The jugular venous pressure may be elevated. Other signs of right heart failure such as hepatic congestion and pedal edema may also eventually develop.
A chronic smouldering rheumatic myocarditis may further reduce left ventricular function. Patients with mitral stenosis also often have aortic stenosis. Some patients will also have mixed mitral regurgitation/stenosis.
Mitral Stenosis in Pregnancy
In pregnancy, the pressure gradient between the left atrium and ventricle is usually increased due to the increase in the heart rate and cardiac output during pregnancy. This can lead to the diagnosis of previously asymptomatic case of mitral stenosis, or worsening of the symptoms of previously diagnosed case.
- ↑ BLAND EF, DUCKETT JONES T (1951). "Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood.". Circulation 4 (6): 836-43. PMID 14879491.
- ↑ Selzer A, Cohn KE (1972). "Natural history of mitral stenosis: a review.". Circulation 45 (4): 878-90. PMID 4552598.
- ↑ Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev CI et al. (2005). "Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation.". Circulation 111 (24): 3296-301. doi:10.1161/CIRCULATIONAHA.104.473165. PMID 15956138.
- ↑ Horstkotte D, Niehues R, Strauer BE (1991). "Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis.". Eur Heart J 12 Suppl B: 55-60. PMID 1936027.
- ↑ 5.0 5.1 Marcus RH, Sareli P, Pocock WA, Barlow JB (1994). "The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae.". Ann Intern Med 120 (3): 177-83. PMID 8043061.
- ↑ Chapter 1: Diseases of the Cardiovascular system > Section: Valvular Heart Disease in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 0-7817-7153-6.
- ↑ Mitral Stenosis: Heart Valve Disorders: Merck Manual Home Edition. Retrieved on 2009-03-14.
- ↑ Gordon SP, Douglas PS, Come PC, Manning WJ (1992). "Two-dimensional and Doppler echocardiographic determinants of the natural history of mitral valve narrowing in patients with rheumatic mitral stenosis: implications for follow-up.". J Am Coll Cardiol 19 (5): 968-73. PMID 1552121.
- ↑ Sagie A, Freitas N, Padial LR, Leavitt M, Morris E, Weyman AE et al. (1996). "Doppler echocardiographic assessment of long-term progression of mitral stenosis in 103 patients: valve area and right heart disease.". J Am Coll Cardiol 28 (2): 472-9. doi:10.1016/0735-1097(96)00153-2. PMID 8800128.
- ↑ Shinoda H, Stern PH (1992). "Diurnal rhythms in Ca transfer into bone, Ca release from bone, and bone resorbing activity in serum of rats.". Am J Physiol 262 (2 Pt 2): R235-40. PMID 1539731.
- ↑ Nazari S, Carli F, Salvi S, Banfi C, Aluffi A, Mourad Z et al. (2000). "Patterns of systolic stress distribution on mitral valve anterior leaflet chordal apparatus. A structural mechanical theoretical analysis.". J Cardiovasc Surg (Torino) 41 (2): 193-202. PMID 10901521.
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies